MyFinsight
Home
Blog
About
Contact
Maturities of short-term
investments,...
$42,500K
Proceeds from royalties
earned under license...
$97K
Proceeds from exercise of
common stock options...
$62K
Net cash and cash
equivalents provided by...
$27,791K
Net cash and cash
equivalents provided by...
$159K
Canceled cashflow
$14,709K
Net decrease in cash
and cash...
-$16,996K
Canceled cashflow
$27,950K
Accounts payable and
accrued liabilities
$10,315K
Stock-based compensation
expense
$7,423K
Depreciation and
amortization expense
$397K
Other non-cash items
-$245K
Purchases of short-term
investments,...
$14,709K
Net cash and cash
equivalents used in...
-$44,946K
Canceled cashflow
$18,380K
Total revenue
$22,681K
Interest income
$1,968K
Net loss
-$60,618K
Canceled cashflow
$24,649K
Accretion on investments,
net of amortization
$990K
Accounts receivable
$839K
Prepaid expenses and
other assets
$524K
Inventories
$294K
Contract liability
-$61K
Total segment
operating...
$55,959K
Total segment
operating...
$8,377K
Total segment
operating...
$7,423K
Total segment
operating expenses-Cost...
$6,286K
Interest expense
$2,441K
Total segment
operating...
$1,783K
Total segment
operating...
$1,726K
Total segment
operating...
$1,214K
Total segment
operating expenses-Other...
$58K
Back
Back
Cash Flow
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)
source: myfinsight.com